SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Wire to Wire Daily Stock Picking -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey L. Henken who wrote (942)7/1/1999 9:33:00 AM
From: Henrik  Read Replies (1) | Respond to of 3514
 
PGLAF - Henrik - 13.6M - 3 15/16 - Bid 3 3/8 - Ask 4 - FDA News

Progen gets go-ahead for anti-cancer trial

10:25
Thursday, 1 July 1999

Sydney - Thursday - July 1: The United States Food and Drug
Administration (FDA) has completed its review and given final
clearance, June 30th, Washington time for Progen's PI-88 anti-cancer
trial.
With final FDA approval, Progen has now met all conditions for
Royal Melbourne Hospital Ethics Committee approval and trials should
commence in July/August.



To: Jeffrey L. Henken who wrote (942)7/1/1999 10:06:00 AM
From: Katie Kommando  Respond to of 3514
 
Thanks Jeff. As always, I appreciate your perspective and attitude. It is refreshing to see some common sense on SI. You nailed the short term ceiling right on with PCES. I also think PCES will turn into gold in the near term and I will be that "hero" your referred to!!

Katie K.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News